Company profile
UK company 01696917, incorporated on 3 February 1983.
Helping you bring inhaled medicines to market - Inhalation Drug Delivery - Vectura
Our specialist capabilities in formulation science, device technology and inhaled development expertise can help you bring DPI, pMDI and nebuliser medicines to market.
Company number 01696917
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
CS01 | Transaction MzUzOTM2NTAzOGFkaXF6a2N4
Published 18 Aug 2026 16:31
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 Feb 2014 to 31 Jul 2015
Nuformix and Vectura will explore pre-competitive applications for the use of cocrystal technology within inhalation formulation and product development for the treatment of respiratory disease. It is hoped the output will provide indications for future product development opportunities and TSB funding will accelerate that process.
1 Feb 2014 to 30 Sep 2014
Vectura is developing a series of particle engineered formulation platforms for delivery of dry powder treatments to the lung. At present the majority of treatments on the market are small molecules, although biomolecules are increasingly being developed as alternatives, particularly in difficult-to-treat diseases. Each inhalation product has unique chall...
